MoFo Life Sciences

May 14, 2025 - AI, Privacy + Data Security
Data Privacy at the Crossroads of AI and Life Sciences: U.S. and EU Perspectives
By: Melissa M. Crespo, Marijn Storm, Marian A. Waldmann Agarwal, Joshua R. Fattal and Katherine Wang
This post is part of MoFo’s 2025 Intersection of AI and Life Sciences blog series. In this blog series, we explore how artificial intelligence is revolutionizing research, innovation, and patient care in the life sciences. Stay tuned for expert insights regarding the impact of
... ›
May 06, 2025 - AI, Intellectual Property
Patent-Eligibility Considerations & Prosecution Strategies for AI-Based Life Sciences Patent Applications
By: Steve Sundberg Ph.D., Anna Yuan and Mehran Arjomand
This post is part of MoFo’s 2025 Intersection of AI and Life Sciences blog series. In this blog series, we explore how artificial intelligence is revolutionizing research, innovation, and patient care in the life sciences. Stay tuned for expert insights regarding the impact of
... ›
April 29, 2025 - AI, FDA
AI Transparency in Healthcare: Navigating a Changing Regulatory Landscape
By: Marijn Storm, Brigid DeCoursey Bondoc and Elena Catherine Klonoski
This post is part of MoFo’s 2025 Intersection of AI and Life Sciences blog series. In this blog series, we explore how artificial intelligence is revolutionizing research, innovation, and patient care in the life sciences. Stay tuned for expert insights regarding the impact of
... ›
April 25, 2025 - AI
Recentive: Raising the Patent-Eligibility Bar in AI-Related Inventions
By: Jonathan Bockman, Jeffrey Gerard Young, Briana Erin Mittleman Ph.D., Joshua A. Crawford and Anna Yuan
This post is part of MoFo’s 2025 Intersection of AI and Life Sciences blog series. In this blog series, we explore how artificial intelligence is revolutionizing research, innovation, and patient care in the life sciences. Stay tuned for expert insights regarding the impact of
... ›
April 09, 2025 - AI, Intellectual Property
Federal Circuit Clarifies Requirements for Prior Art Under Pre-AIA 35 U.S.C. § 102(e)
By: Lisa N. Silverman Ph.D., Mehran Arjomand and Marisa B. Sanders
Knowing what qualifies as prior art is a core requirement of patent practitioners—whether in life sciences, in the technology sectors or in post-grant proceedings. It is important to keep abreast of changes to the rules, especially if the Federal Circuit weighs in. On March 24, 2025,
... ›
March 25, 2025 - AI, Healthcare
AI Agent as a Service in Medtech: Key Considerations for Commercial Contracts
By: Matthew A. Ferry and Tricia Matibag
This post is part of MoFo’s 2025 Intersection of AI and Life Sciences blog series. In this blog series, we explore how artificial intelligence is revolutionizing research, innovation, and patient care in the life sciences. Stay tuned for expert insights regarding the impact of
... ›
March 04, 2025 - AI, Intellectual Property
Navigating Inventorship in the Era of AI-Assisted Drug Discovery
By: Caressa Tsai Ph.D., Joshua A. Crawford and Meghan McLean Poon Ph.D.
This post is part of MoFo’s 2025 Intersection of AI and Life Sciences blog series. In this blog series, we explore how artificial intelligence is revolutionizing research, innovation, and patient care in the life sciences. Stay tuned for expert insights regarding the impact of
... ›
February 11, 2025 - AI, Intellectual Property
Patents and Trade Secrets in AI and Life Sciences
By: Briana Erin Mittleman Ph.D., Meghan McLean Poon Ph.D. and Joshua A. Crawford
This post is part of MoFo’s 2025 Intersection of AI and Life Sciences blog series. In this blog series, we explore how artificial intelligence is revolutionizing research, innovation, and patient care in the life sciences. Stay tuned for expert insights regarding the impact of
... ›
January 21, 2025 - AI, FDA, Regulatory
FDA Draft Guidance on Artificial Intelligence-Enabled Device Software Functions
By: Ashley E. Quinn, Brigid DeCoursey Bondoc, Erin M. Bosman, Julie Y. Park and Elena Catherine Klonoski
This post is part of MoFo’s 2025 Intersection of AI and Life Sciences blog series. In this blog series, we explore how artificial intelligence is revolutionizing research, innovation, and patient care in the life sciences. Stay tuned for expert insights regarding the impact of
... ›
January 16, 2025 - FDA, AI, Regulatory
FDA Releases Draft Guidance on Evaluating the Risk and Credibility of AI Used in Establishing Drug and Device Safety, Effectiveness, and Quality
By: Ashley E. Quinn, Brigid DeCoursey Bondoc, Erin M. Bosman, Julie Y. Park and Elena Catherine Klonoski
This post is part of MoFo’s 2025 Intersection of AI and Life Sciences blog series. In this blog series, we explore how artificial intelligence is revolutionizing research, innovation, and patient care in the life sciences. Stay tuned for expert insights regarding the impact of
... ›

Topic Archives: AI

Data Privacy at the Crossroads of AI and Life Sciences: U.S. and EU Perspectives

By: Melissa M. Crespo, Marijn Storm, Marian A. Waldmann Agarwal, Joshua R. Fattal and Katherine Wang

Patent-Eligibility Considerations & Prosecution Strategies for AI-Based Life Sciences Patent Applications

By: Steve Sundberg Ph.D., Anna Yuan and Mehran Arjomand

AI Transparency in Healthcare: Navigating a Changing Regulatory Landscape

By: Marijn Storm, Brigid DeCoursey Bondoc and Elena Catherine Klonoski

Recentive: Raising the Patent-Eligibility Bar in AI-Related Inventions

By: Jonathan Bockman, Jeffrey Gerard Young, Briana Erin Mittleman Ph.D., Joshua A. Crawford and Anna Yuan

Federal Circuit Clarifies Requirements for Prior Art Under Pre-AIA 35 U.S.C. § 102(e)

By: Lisa N. Silverman Ph.D., Mehran Arjomand and Marisa B. Sanders

AI Agent as a Service in Medtech: Key Considerations for Commercial Contracts

By: Matthew A. Ferry and Tricia Matibag

Navigating Inventorship in the Era of AI-Assisted Drug Discovery

By: Caressa Tsai Ph.D., Joshua A. Crawford and Meghan McLean Poon Ph.D.

Patents and Trade Secrets in AI and Life Sciences

By: Briana Erin Mittleman Ph.D., Meghan McLean Poon Ph.D. and Joshua A. Crawford

FDA Draft Guidance on Artificial Intelligence-Enabled Device Software Functions

By: Ashley E. Quinn, Brigid DeCoursey Bondoc, Erin M. Bosman, Julie Y. Park and Elena Catherine Klonoski

FDA Releases Draft Guidance on Evaluating the Risk and Credibility of AI Used in Establishing Drug and Device Safety, Effectiveness, and Quality

By: Ashley E. Quinn, Brigid DeCoursey Bondoc, Erin M. Bosman, Julie Y. Park and Elena Catherine Klonoski